Cannabidiol and Amisulpride Improve Cognition in Acute Schizophrenia in an Explorative, Double-Blind, Active-Controlled, Randomized Clinical Trial

Cannabidiol and Amisulpride Improve Cognition in Acute Schizophrenia in an Explorative, Double-Blind, Active-Controlled, Randomized Clinical Trial

Cannabidiol (CBD), a principal phytocannabinoid constituent, has demonstrated antipsychotic properties in recent clinical trials. While it has also been suggested a promising candidate for the treatment of neurodegenerative disorders, it failed to demonstrate efficacy in cognitive impairments associ...

Full description

Bibliographic Details
Main Authors: F. Markus Leweke, Cathrin Rohleder, Christoph W. Gerth, Martin Hellmich, Ralf Pukrop, Dagmar Koethe
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-04-01
Series:Frontiers in Pharmacology
Subjects:
cognition
neuropsychological function
cannabidiol
schizophrenia
endocannabinoids
RCT
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2021.614811/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2021.614811/full

Similar Items